-

Transgene Announces Investor Meetings for January 2022

STRASBOURG, France--(BUSINESS WIRE)--Regulatory News:

TRANSGENE (Paris:TNG) today announces that Management will participate in the upcoming investor events set out below.

Transgene will meet institutional investors at the 11th Annual LifeSci Advisors Corporate Access Event (virtual event) from January 5th to 7th, 2022.

The Company will also attend:

  • 25th ODDO BHF Digital Forum (virtual): January 6, 7, 10 and 11, 2022
  • Biotech Showcase Investor Conference (virtual):
    • January 10 to 12, 2022, in conjunction with the J.P. Morgan Healthcare conference
    • January 17 to 19, 2022
  • Biomed Event (Paris): January 26, 2022

About Transgene
Transgene (Euronext: TNG) is a biotechnology company focused on designing and developing targeted immunotherapies for the treatment of cancer. Transgene’s programs utilize viral vector technology with the goal of indirectly or directly killing cancer cells.
The Company’s clinical-stage programs consist of two therapeutic vaccines (TG4001 for the treatment of HPV-positive cancers, and TG4050, the first individualized therapeutic vaccine based on the myvac® platform) as well as two oncolytic viruses (TG6002 for the treatment of solid tumors, and BT-001, the first oncolytic virus based on the Invir.IO™ platform).
With Transgene’s myvac® platform, therapeutic vaccination enters the field of precision medicine with a novel immunotherapy that is fully tailored to each individual. The myvac® approach allows the generation of a virus-based immunotherapy that encodes patient-specific mutations identified and selected by Artificial Intelligence capabilities provided by its partner NEC.
With its proprietary platform Invir.IO™, Transgene is building on its viral vector engineering expertise to design a new generation of multifunctional oncolytic viruses. Transgene has an ongoing Invir.IO™ collaboration with AstraZeneca.
Additional information about Transgene is available at: www.transgene.fr
Follow us on Twitter: @TransgeneSA

Contacts

Transgene:
Lucie Larguier / Jean-Philippe Del
Director Corporate Communications & IR
+33 (0)3 88 27 91 04 / 00
investorrelations@transgene.fr

Media Transgene:
MEDiSTRAVA Consulting
David Dible/Sylvie Berrebi
+44 (0)7714 306525
transgene@medistrava.com

TRANSGENE

BOURSE:TNG

Release Versions

Contacts

Transgene:
Lucie Larguier / Jean-Philippe Del
Director Corporate Communications & IR
+33 (0)3 88 27 91 04 / 00
investorrelations@transgene.fr

Media Transgene:
MEDiSTRAVA Consulting
David Dible/Sylvie Berrebi
+44 (0)7714 306525
transgene@medistrava.com

More News From TRANSGENE

Transgene Announces Upcoming Investor Meetings

STRASBOURG, France--(BUSINESS WIRE)--Regulatory News: TRANSGENE (Paris:TNG) today announces that Management will participate in several investor events in the upcoming investor events, as set out below. Transgene will meet institutional investors at the 13th Annual LifeSci Advisors Corporate Access Event in San Francisco from January 8 to 10, 2024, in conjunction with the J.P. Morgan Healthcare conference. The Company will also attend: 27th ODDO BHF Forum (virtual): January 15-16, 2024; Invest...

Transgene Strengthens its Leadership Team to Accelerate its Growth Strategy

STRASBOURG, France--(BUSINESS WIRE)--Regulatory News: Transgene (Euronext Paris: TNG) (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, is pleased to announce the appointment of Arnaud Dubarry as Chief Financial Officer (CFO), effective January 1, 2024. Arnaud Dubarry will be based in Strasbourg and will be responsible for all aspects of the Company’s financial strategy, management and operations to accelerate the development of it...

Transgene Reports Business Update and Q3 2023 Financial Position

STRASBOURG, France--(BUSINESS WIRE)--Regulatory News: Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announces its business update and its financial position for the quarter ending September 30, 2023. During the third quarter of 2023, Transgene’s clinical-stage immunotherapy portfolio continued to advance. Notable progress included the treatment of the first patient in the Part B of Phase I trial assess...
Back to Newsroom